I Travel for Global Oncology: The Tale of My Great Journey at the University of Lahore in Pakistan
By Khalid El Bairi, MDOn a beautiful morning in early October 2022, I received a WhatsApp message from an enthusiastic young professor of pharmacy, Dr. Faisal Gulzar, who invited me to deliver presentations in a country very far from my home in Morocco—Pakistan! A country that I've never visited and that I mostly know...
Ovarian Cancer Risk Lower With Daily Aspirin, Despite Genetics
The new findings indicate frequent aspirin use provides a protective effect against nonmucinous ovarian cancer, regardless of a person's genetic susceptibility. Medscape Medical News
Renewed Calls for Fallopian Tube Removal to Avoid Ovarian Cancer
Renewed calls for all women to consider having their fallopian tubes removed once they have finished with childbearing come from the Ovarian Cancer Research Alliance. Medscape Medical News
FDA Expands Approval of Imaging Agent Cytalux for Lung Cancer
The expanded indication for pafolacianine (Cytalux) follows an initial approval in November 2021 for use in patients with ovarian cancer. Medscape Medical News
Test Predicts Which BC Patients Benefit From Ovarian Suppression
Using the Breast Cancer Index earlier could identify premenopausal HR+ breast cancer patients who benefit from ovarian function suppression, suggests analysis. Medscape Medical News
New Findings on Rare Mucinous Ovarian Cancer May Change Tx
A global study of the microscopic patterns of cell growth in samples taken from women with this rare form of ovarian cancer may lead to treatment changes for some. Medscape Medical News
Preventing Doxorubicin-Induced Hand-Foot Syndrome
Dexamethasone plus wrist and ankle cooling may prevent hand-foot syndrome from doxorubicin in patients with ovarian cancer. The study was published as a preprint and has not yet been peer reviewed. First Look
Drug Companies Withdraw PARPi Indications for Ovarian Cancer
Zejula, Lynparza, and Rubraca have been voluntarily withdrawn for late-line ovarian cancer treatment indications over concerns surrounding an increased risk for death. Medscape Medical News
When Too Much Treatment Creates More Harm Than Good
Despite guidelines advising against intensive end-of-life care, many women with terminal ovarian cancer receive an aggressive intervention. Medscape Medical News
Large Benefit From Ovarian Function Suppression in Breast Cancer
Eight-year follow-up of the ASTRRA trial confirms and extends support for adding 2 years of ovarian function suppression with goserelin to tamoxifen, compared with tamoxifen alone. Medscape Medical News
